INDEX

Volume Ten—January through December 1976

DRUG INTELLIGENCE AND CLINICAL PHARMACY

January	Pages 1 - 64	July	Pages 365 - 428
February	Pages 65 - 128	August	Pages 429 - 484
March	Pages 129 - 192	September	Pages 485 - 548
April	Pages 193 - 244	October	Pages 549 - 612
May	Pages 245 - 300	November	Pages 613 - 676
June	Pages 301 - 364	December	Pages 677 - 732

A

Absorption Rate Constant, nomograph, 77; nomogram (letter) 350
Abuse of medicines, self-medication, 16; prescription, 94; recommendations, 172; (ed) 51
Acetaminophen, elimination kinetics (ab) 425; kinetics of, effect of dialysis on (ab) 241
Adenine Arabinoside, therapy of herpes zoster (ab) 664
Adrenocorticosteroids, pseudotumor cerebri, 566
Adverse Drug Reactions
aluminum intoxication, death, 239
antiallergy injections, desensitized, neuropathy (ab) 124
anticholinergic, agranulocytosis (ab) 667
antipsychotic drugs (letters) 54, 114, 294
aspirin, intolerance in childhood asthma (ab) 57
atropine, adverse effects on patients with sinus bradycardia (ab) 58; in acute myocardial infarction patients, sustained sinus tachycardia (ab) 58; PVC's increased (ab) 58; toxic psychosis (ab) 58; ventricular tachycardia or fibrillation (ab) 58; IV, ventricular fibrillation (ab) 608
bleomycin, fatal pulmonary reaction (ab) 359
camphor, poisoning (ab) 359; 631
cancer chemotherapy, alterations in nail pigment, 716
cefamandole, phlebitis (ab) 473
cephalexin, nephropathy (ab) 124
cephalothin, phlebitis (ab) 473
cephapirin, phlebitis (ab) 473
chlorpromazine, agranulocytosis (ab) 667; leukopenia, 562
chlorpropamide, granulomas (ab) 296
clozapine, agranulocytosis (ab) 667
diazoxide, anginal syndrome (ab) 296; cerebral ischemia (ab) 296; hypotension (ab) 296; myocardial infarction (ab) 296
epinephrine, in enflurane anesthesia, ventricular arrhythmias (ab) 57; in halothane anesthesia, ventricular arrhythmias (ab) 57
estrogen, conjugated, endometrial carcinoma (ab) 185; 667
ethchlorvynol, pulmonary edema, 239
gentamicin, acute renal failure, 716; inactivated by penicillins (ab) 718
heparin, thrombocytopenia (ab) 546
hydergine, sinus bradycardia (ab) 185
IV drug abuse, serratia marcescens endocarditis, 239
levodopa therapy, long term, thrombocytopenia (ab) 476
lithium, irreversible inhibition of choline transport system (ab) 607
methadone, side effects, 716
methyldopa withdrawal, rebound hypertension (ab) 476
methylphenidate hydrochloride, tics in children (ab) 359
minocycline, dizziness (ab) 607; vertigo (ab) 607; ataxia (ab) 607; weakness (ab) 607; nausea (ab) 607; vomiting (ab) 607
monoamine oxidase inhibitors, agranulocytosis (ab) 667
nitroglycerin, hypotension, 716
oral contraceptives, carbohydrate tolerance, changes in (ab) 57; gallbladder disease (ab) 296
oxprenolol, oral, circulatory collapse (ab) 124
pancreatic extract, high dose, hyperuricosuria (ab) 546
pentazocine, iatrogenic muscle fibrosis (ab) 124; psychosis (ab) 57
phenobarbital, osteomalacia (ab) 239
phenothiazine, agranulocytosis (ab) 667
phenytoin, osteomalacia (ab) 239
propoxyphene overdose (letters) 596
propranolol, psoriasiform cutaneous eruptions (ab) 608
thioridazine, agranulocytosis (ab) 667
tricyclic antidepressants, 380; (letter) 711, overdoses (letters) 597, 652; memory difficulty (ab) 667; poisoning, coma (ab) 607; systolic blood pressure (ab) 607
trimethaphan camsylate, respiratory paralysis (ab) 607
Adverse Drug Reactions—A Matter of Opinion (ab) 473
Advice to Young Students (ed) 651
Akrivos, George (co-author) letter, drug product information disclosure, 113
Alcohol, consumption and economic changes (ab) 353; interaction with chlordiazepoxide (ab) 56; interaction wih flupenthixole (ab) 56
Alexander, Michael M. (author) abstracts, 57, 59
Allergy, penicillin desensitization, 333; (letter) 540
Altemuehle, Paul B. (author) book review, 661
Aluminum, intoxication, death (ab) 239
American Board of Clinical Pharmacy, application for board certification, 171; articles of organization, 168; (ed) 180; (letter) 292, 419; list of members, 171
American Institute of the History of Pharmacy, symposium on clinical pharmacy, 506
American Pharmaceutical Association, F.I.P. representative, 36
Amikacin, in the newborn, kinetics and dose calculations of (ab) 546; therapy, for serious gram-negative bacillary infections (ab) 186; compared with kanamycin, 717
Amino Acids, effects of drugs on, 8
Amitriptyline, overdoses with tricyclic antidepressants, 380; and flupenthixol, comparison of in outpatients (ab) 545
Amoxicillin, treatment of chronic enteric fever (ab) 297; trimethoprim-sulfamethoxazole, comparison of (ab) 241
Amphotericin B, interaction with mannitol (ab) 472
Ampicillin, cephalosporin derivatives, comparative evaluations of (ab) 666
Ampuls, value of filtering (letter) 293
Andrews, Theodora (author) book review, 421
Angaran, David M. (author) The Cynic Commission — A Communication From Dr. Clinical, 394; (ed) Random Thoughts, 463
Antiallergy Injections, desensitized, neuropathy (ab) 124
Antibiotics, in emphysema and bronchitis, 200; therapy, partial, in H. Influenzae Meningitis (ab) 58; use control, 258
Anticholinergic, agranulocytosis (ab) 667
Anticonvulsants, clinical pharmacokinetics of (ab) 608; fluctuation of levels in diabetic ketoacidosis, 436; interaction with quinidine (ab) 358
Antidepressants, tricyclic, 380; (letters) 600; overdose (letter) 711
Antidotes, for tricyclic antidepressants, 380
Anti-Human Lymphocyte Globulin, heparin precipitate (letter) 654
Antipsychotic Drugs (letters) regarding drug interaction article, 54; (letter) 114; (letter) 294
Antipyrine, interaction, quinine (ab) 184
Arkwright, Thomas W. (author) abstracts, 59; letter concerning patient compliance, 115
Aronow, Regine (co-author) Implications of Camphor Poisoning—Therapeutic and Administrative, 631
Arrington, Wendell S. (author) letter concerning the 12th annual meeting of Drug Information Association, 294
Ascione, Frank J. (author) letter concerning an evaluation of drug interactions, 233
Ascorbic acid (ab) 184; interaction with urinary uric acid (ab) 472
Ashby, Daniel M. (co-author) Trace Element Concentrations in Commercially Available Solutions, 74
Aspirin, intolerance in childhood asthma (ab) 57; naproxen in rheumatoid arthritis (ab) 666
Atropine, adverse effects on patients with sinus bradycardia (ab) 58; in acute myocardial infarction patients, PVC's increased (ab) 58; sustained sinus tachycardia (ab) 58; toxic psychosis (ab) 58; ventricular tachycardia or fibrillation (ab) 58; IV, ventricular fibrillation (ab) 608
Authority of the Clinical Pharmacist (letter) 657
Author's Guidelines, for manuscripts, 15
Azathioprine, in diffuse lupus nephritis (ab) 664; interaction with prednisone (ab) 56

B

Balla, A. (author) letter concerning clinical pharmacy experiences in psychiatric hospital, 653
Barbiturates, drug interactions, 570
Bauch, Robert (co-author) Medication Data Sheets — Aid to Patient Education, 448
Becker, Charles E. (co-author) letter, tricyclic antidepressant overdose, 711
Becker, Rita M. (author) letter updating of tartrazine article, 606
Beclomethasone Dipropionate, evaluation, 635
Behavioral Science, in patient education, 314
Bender, John F. (co-author) A Benzquinamide-Induced Extrapyramidal Reaction, 638
Benfante, Paule (ed) Advice to Young Students, 651
Benowitz, Neal W. (co-author) letter, tricyclic antidepressant overdose, 711
Benson, Roger A. (co-author) Evolution of the Clinical Pharmacy Concept, 506
Berman, Alex (ed) Some Observations on the Report of the Study Commission on Pharmacy, 288
Benzquinamide, induced extrapyramidal reaction, 638
Bioavailability, of enteric coated tablets, 588; reduced, digoxin, 680; superior in capsules, digoxin (ab) 297; sulfadiazine, 402
Blake, Martin I. (co-author) letter, drug product information disclosure, 113
Blaufuss, John C. (author) letter, history in pharmacy, 655
Bleomycin, fatal pulmonary reaction (ab) 359
Board Certification (letter) 349
Book Reviews, See Literature
Books Received
Biotransformation der Arzneimittel, Eine Systematische Ubersicht (K.-H. Beyer) 543
The Catharanthus Alkaloids (W. I. Taylor and N. R. Farnsworth) 295
Drug-Induced Blood Disorders (C. G. de Gruchy) 357
Enzyme Reactions and Enzyme Systems (C. Walter) 357
Food Emulsions (S. Friberg) 543
Good Manufacturing Practices for Pharmaceuticals (Willig, Tuckerman and Hitchings) 715
Guide des Interactions Médicamenteuses et Répertoire des Médicaments par Classes Thérapeutiques (M. Neuman) 661
Guidelines for Evaluation of Drugs for Use in Man (WHO Scientific Group) 295
High-Speed Liquid Chromatography (P. Rajcasanyi and E. Rajcasanyi) 357
Immunity and Cancer in Man, An Introduction (Immunology Series, Vol. 3) A. E. Reif & C. M. Southam et al.) 189
Infection Control in the Hospital (P. F. Wehrle, et al.) 543
Introducing WHO (WHO) 543
Lipid Chromatographic Analysis, 2nd Ed., Vol. 1 (G. V. Marinetti) 471
Lipid Chromatographic Analysis, 2nd ed., Volume 2 (G. V. Marinetti) 715
Medication Law and Behavior (J. T. Gibson) 543
Methadone: Experiences and Issues (C. D. Chambers and L. Brill) 356
Methods in Narcotics Research (Modern

Pharmacology - Toxicology, Vol. 5) (S. Ehrenpreis) 189
Microencapsulation (J. R. Nixon) 357
Our Chemical Culture (M. J. Sommers et. al.) 661
Pharmacokinetics (M. Gibaldi and D. Perrier) 357
Pharmacokinetics of Hypnotic Drugs (D. d. Breimer) 543
Pharmacological Modifications by Evoked Brain Potentials (A. A. Borbély) 295
Pro-drugs as Novel Drug Delivery Systems (B. Higuchi and V. Stella) 543
Protein Nutrition Quality of Foods and Feeds, Pt. 2 (Nutrition and Clinical Nutrition, Vol. 1) (M. Friedman) 189
Remarkable Pharmacists (W. L. Blockstein and C. B. Granberg) 357
Selected Bibliography on Detection of Dependence-Producing Drugs in Body Fluids (T. L. Chrusciel and M. Chrusciel) 295
Synaptic Receptors - Isolation and Molecular Biology (Modern Pharmacology - Toxicology Series, Vol. 4) (E. DeRobertis) 189
The West Cornwall System for the Control of Drugs in Small Hospitals (S. Ellis) 295
Books Reviewed
Advances in Behavioral Biology, Volume 6: Psychopharmacology and Aging (C. Eisdorfer and W. E. Fann) 469
The American Alcoholic - The Nature-Nurture Controversy in Alcoholic Research and Therapy (W. Madsen) 422
Clinical Pharmacy Handbook for Patient Counseling (S. E. Apelgren and B. Rowles) 423
Compendium of Pharmaceuticals and Specialties 1976 (G. N. Rotenberg, N. L. Otterbein and F. N. Hughes) 542
Drug Effects in Hospitalized Patients (R. R. Miller and D. J. Greenblatt) 660
Drug Metabolism: Chemical and Biochemical Aspects (B. Testa and P. Jenner) 661
Evaluations of Drug Interactions, 2nd Ed. (Drug Interactions Evaluating Program) 659
The Fate of Drugs in the Organism: A Bibliographic Survey, Vol. 1, 2, 3 (Société Francaise des Sciences et Techniques Pharmaceutiques Working Group) 660
Guide to Drug Information (W. Sewell) 421
A Handbook on Drug and Alcohol Abuse - The Biomedical Aspects (F. G. and A. D. Hofmann) 421
Handbook of Veterinary Drugs (I. S. Rossoff) 661
Health Aspects of Human Rights With Special Reference to Developments in Biology and Medicine (World Health Organization) 469
Heroin Dependency (B. Stimmel) 422
Horizons in Clinical Pharmacology, Volume 6: Modern Pharmacology - Toxicology Series (R. F. Palmer) 714
Innovative Medical-Psychiatric Therapies (R. M. Swinn and R. G. Neigel) 659
Inpharma (ADIS Press) 189
Lehrbuch der Pharmazeutischen Technologie (Textbook of Pharmaceutical Technology) (Prof. Dr. R. Voigt) 715
Nonproprietary Names for Pharmaceutical Substances: Twentieth Report of the WHO Expert Committee (World Health Organization) 715
The Patient, Death and the Family (S. B. Troup and W. A. Greene) 470
Pharmaceutical Services in the Long-Term Care Facility (Am. Pharm. Assoc., Am. Soc. of Hosp. Pharm., and Am. Hlth Care Assoc.) 121
Pharmacy and the Law (C. T. DeMarco) 188
Pocket Consult, Diuretics (M. J. Reilly) 356
Principles and Methods of Pharmacy Management (H. A. Smith) 189
Principles and Techniques of Human Research and Therapeutics, Vol. III: Pharmacokinetics, Drug Metabolism and Drug Interactions (F. G. McMahon) 122
Principles of Pharmaceutical Marketing (M C. Smith) 189
Progress in Medicinal Chemistry (G. P. Ellis and G. B. West) 543
Radiopharmaceuticals (G. Sobramanian) 714
Self-Assessment of Current Knowledge in Clinical Pharmacy (P. P. Gerbino) 471
Steroids and Shock (T. M. Glenn) 470
Therapeutic Effectiveness of Methadone Maintenance Programs in the USA (S. S. Wilmarth & A. Goldstein, Geneva World Health Organization) 121
The Use of Antibiotics (A. Kucers and N. McK. Bennett) 542
WHO Expert Committee on Specifications for Pharmaceutical Preparation: Twenty-Fifth Report (World Health Organization) 188
Bosso, John A. (author) Pediatric Clinical Pharmacy Case Study — Pseudotumor Cerebri Associated With Drug Therapy, 566
Bouchard, Vincent E. (author) letter concerning attempt to get former pharmacy interns, residents and students to organize Univ. of Michigan Hospital Pharmacy Alumni Association, 234
Bowers, Charles D. (co-editor) Drug Evaluation Data, 216
Brodie, Donald C. (co-author) Evolution of the Clinical Pharmacy Concept, 506
Bronchiectasis, diagnoses & treatment of cough, 640
Bronchitis, chronic and emphysema, 200
Bronchodilator Drugs, in bronchitis and emphysema, 200
Brown, John (co-author) letter, drug used in post kidney transplant, 654
Brown, Susan R. (co-author) Interactions of CNS Drugs—Hypnotics and Sedatives, 570
Bruck, Erika (co-author) Fluctuations of Serum Phenobarbital and Phenytoin Concentrations During Two Acute Episodes of Diabetic Ketoacidosis - Report of a Case, 436
Bryan, Candace K. (author) Commentary — Patient Information vs. Patient Education, 314; (co-author) Overdoses With Tricyclic Antidepressants, 380
B.Sc. Pharmacists, value of (letter) 113
Buncher, C. R. (co-author) Bioavailability of Sulfadiazine Tablets in Man, 402
Burkle, Wayne S. (author) Drug Evaluation Data, Tobramycin and Gentamicin, 43
Burton, Diane Lea (author) abstracts, 58, 125, 126

C

cAMP-PDE, cromoglycate inhibition of (ab) 424
Cacace, Larry G. (co-author) Alpha-Methyldopa (Aldomet) Hepatitis — Report of a Case and Review of the Literature, 144
Calcitonin-Salmon, in multiple myeloma induced hypercalcemia (letter) 52
Calcium Carbonate, and sodium fluoride, multiple-myeloma bone disease: effect of (ab) 298
Calvert, Jon C. (author) Cough Differential Diagnosis and Treatment, 640
Camphor, poisoning (ab) 359; 631
Canada, Andrew T. (co-author) letter, article about overdose with tricyclic antidepressants, 600; (author) letter, review of Carbidopa and Levodopa Evaluation, 290
Carbidopa, levodopa, evaluation, 84; comment on (letter) 290
Carbohydrates, effects of drugs on, 8
Carlson, James D. (author) letter, the different methods of penicillin skin testing, 540
Carmustine, investigational drug information, 48
Case Studies
alpha-methyldopa hepatitis, 144
benzquinamide-induced extrapyramidal reaction, 638
camphor poisoning, 631
chlorpromazine leukopenia & hepatotoxicity, 562
choice of IV solution, 339
digitalis-induced arrhythmias, 467
fluctuations of phenobarbital & phenytoin concentrations in diabetic ketoacidosis, 436
overdose with tricyclic antidepressants, 380
penicillin desensitization, 333
phenothiazines, 562
pseudotumor cerebri associated with drug therapy, 566
propoxyphene overdose and death, (letter), 596
Cefamandole, as compared with cephalothin (ab) 360; humans, pharmacology of (ab) 298; phlebitis (ab) 473; pharmacokinetics, 718
Cefazolin, kinetics and dialyzability of (ab) 545; IV pharmacokinetics, 718
Cefuroxime, pharmacokinetics (ab) 477
Cephalexin, nephropathy (ab) 124; phlebitis (ab) 473
Cephalosporin Derivatives, ampicillin, comparative evaluations of (ab) 666; cephalosporin utilization, 265
Cephalothin, as compared with cefamandole (ab) 360; phlebitis (ab) 473; pharmacokinetics, 718
Cephapirin, pharmacokinetics, 718
Cephradine, pharmacokinetics, 717
Chalmers, Robert K. (author) letter about clinical scientist concept, 601
CHF, effect on quinidine kinetics (ab) 126
Children, as patients, 498
Child-Resistant Packaging, 698
Chlordiazepoxide, interaction with alcohol (ab) 56
Chlorpromazine, induced leukopenia & hepatotoxicity, 562; agranulocytosis (ab) 667
Chlorpropamide, granulomas (ab) 296
Chlozapine, agranulocytosis (ab) 667
Chronic Bronchitis, 200
Clinical Pharmacists, roles, on nursing home team, 268; in patient compliance, 386
Clinical Pharmacy
board certification (letter) 349; author's reply, 350
cost benefits of (letter) 181
curriculum, 409, 522
education and practice, patterns in US, 511
evolution of concept, 506
faculty, 409
historical perspective, 505
legal aspects, 444
national health insurance, implications of, 529
practice, levels of (ed) 534; (ed) 651; (ed) 710
psychiatric hospital, in, (letter) 466, (letter) 653
roles, 283, 386, (ed) 593; role pioneering (letter) 655
Clinical Scientist Concept (letter) 601; levels of pharmacy practice (ed) 534
Clofibrate, halofenate, and placebo, trials with (ab) 425
Clonazepam, evaluation, 216
Clonidine, pharmacokinetics of (ab) 298
Clonopin, evaluation, 216
Clorazepate, potassium and nordiazepam, effects on sleep (ab) 718
Coarse, James F. (co-author) Antibiotic Use Control, 258
Coats, Eugene A. (author) book review, 543
Coblio, Nicholas A. (author) letter, clinical pharmacy in a psychiatric hospital, 466
Coffler, Duane E. (author) letter, antipsychotic drug interactions, 114
Cohen, Manley (co-author) Alpha-Methyldopa (Aldomet) Hepatitis - Report of a Case and Review of the Literature, 144
Cohon, Monte S. (author) book review, 423
Communication with children & parents, 498
Community Pharmacists, roles in drug interaction surveillance, 274; (letter) 606; medication data sheets, 448
Competency, of community pharmacists in drug interaction surveillance, 274
Compliance, See **Patient Compliance**
Compounding Accuracy, of hospital pharmacists (letter) 465
Compounding by Nurses, legal issues, 444
Consumers' Attitudes hypertension screening, 283
Containers, See packaging
Continuing Education in California (letter) 351
Copper, in IV solutions, 74
Cornelius, William A. (author) letter, aids to assist in patient compliance, 541; letter, methods of finding information on patient compliance, 537
Correction, in article entitled In-Vitro Determination of the Resistance of Commercial Enteric-Coating to Acidic Conditions, 588, Figures 1 and 2 must be reversed; to trace element article (letter) 466
Cost Benefits, of clinical pharmacy (letter) 181
Costs, Comparative, two cephalosporins, cefazolin and cephalothin (letter) 655
Costs, health care, team approach (ed.) 709
Council of Europe, Working Party (authors) Abuse of Medicines, I. Self Melication, 16; II. Prescription Medicines, 94; III. General Recommendations, 172
Counseling, the physician, 330; the patient (editorial) 416; See also **Patient Counseling**
Cough, diagnosis and treatment, 640
Cradock, James C. (co-editor) Investigational Drug Information, 48
Cunha, Burke A. (co-author) letter, the comparative costs of two cephalosporins, cefazolin and cephalothin, 655
Cyclophosphamide, in diffuse lupus nephritis (ab) 664
Cynic Commission, the, 394

D

Dacarbazine, investigational drug information, 48
D'Angelo, Angele (ed) Strengths of the Woman Practitioner, 50
Davignon, J. Paul (co-editor) Investigational Drug Information, 48
Decker, Edward L. (co-author) Leukopenia and Hepatotoxicity as a Possible Consequence of Chlorpromazine Administration, 562
Degrees, honorary (letter), 114; five-year Pharm.D., 511; value of B.Sc. pharmacists, letter, 113; Pharm.D., 153; two professional, 330; letter, 537; Pharm.D. guidelines, 409
de Haen, Paul (author) Is There a Drug Lag? - Effect of Legislation on the Introduction of Drugs, 86
Deliganis, Sam G. (co-author) Rational Fluid and Electrolyte Therapy Utilization Review, Part I, 339

Dent, Larry A. (co-author) letter, tolbutamide-phenylbutazone interaction, 711
Depo-medroxyprogesterone, A New Treatment for Hirsutism (ab) 186
Desensitization, penicillin, 333
Desferrioxamine, use of in iron overload (ab) 608
Desipramine, accidental poisoning (letter) 52
Detail Men, role in drug prescribing, 321
Devenport, Jean Kuwahara (co-author) Role of the Clinical Pharmacist on a Nursing Home Care Team, 268
Diabetic Ketoacidosis, fluctuations of serum phenobarbital & phenytoin serum levels, 436
Diazoxide, anginal syndrome (ab) 296; hypotension (ab) 296; myocardial infarction (ab) 296; right hemiplegia (ab) 296
Dicloxacillin in Cystic Fibrosis, enhanced excretion of (ab) 297
Diet, and drugs, 8
Digitalis Assay, and its clinical application (ab) 360
Digitalis-Induced Cardiac Arrhythmias (letter) 467
Digitoxin in Renal Failure, disposition of (ab) 426
Digoxin, apparent resistance to, hyperthyroidism (letter) 654; biliary excretion of (ab) 426; in capsules, superior bioavailability of (ab) 297; oral, completely absorbed (ab) 545; reduced bioavailability, 680; slow IV infusion (letter) 417
Disintegration, of enteric salicylate tablets, 588; time, sulfadiazine, 402
Dissolution Characteristics, of sulfadiazine, 402
Dr. Clinical, The Cynic Commission, 394; comment on series (letter) 656; out of place (letter) 536; stimulates (letter) 656
Doctor of Pharmacy Degree, 153; two degrees, 330; guidelines, 409; See also **Degrees**
Dogs, public health implications (ab) 237
Dopamine Dosage (letter) 183; error in letter, 351
Dorr, Robert T. (author) letter, the guidelines for intravenous drugs, 417
Doxycycline, in serum and in thoracic duct lymph, concentrations of (ab) 666
Dozzi, Amelia M. (author) letter congratulating pharmacy isolation editorial, 657
Drug Absorption, absorption rate nomograph, 77; barbiturate interactions, 570
Drug Abuse (ed) 51; computers used, aid control, (ab) 120; recommendations to control, 8; IV, 239
Drug Actions, Interactions and Reactions, 56, 124, 184, 239, 296, 358, 424, 472, 544, 607, 664, 716
Drug Administration, guidelines for IV drugs, 206; to the elderly (ab) 236; legal issues, 444; nurses time involved, 458
Drug Advertising, influence on prescribing, 321
Drug Consumption, studies, 321; and elderly, 398
Drug Coverage Under Insurance, 529
Drug Defaulting, 314; dispensing, 330; distribution systems, 458; dosage, 77
Drug Distribution Systems, impact on nurses time, 458
Drug Dosage, individualization of (ab) 359
Drug-Drug Interaction, surveillance, 274
Drug Evaluation Data, beclomethasone dipropionate, 635; carbidopa and levodopa, 84; clonazepam, 216; tobramycin and gentamicin, 43
"Drug-Free" Diagnosis, significance and importance of (ed) 111
Drug Information Association, 12th Annual Meeting (letter) 294
Drug Information, for prescribers and dispensers (ab) 353
Drug Interaction, antipsychotic (letter) 114; evaluation of (letter) 233
Drug Interactions
alcohol-chlordiazepoxide (ab) 56; flupenthixole (ab) 56
amphotericin B-mannitol (ab) 472
anticonvulsant drugs-quinidine (ab) 358
antipyrine-quinine (ab) 184
ascorbic acid (ab) 184; urinary uric acid (ab) 472
azathioprine-prednisone (ab) 56
chlordiazepoxide-alcohol (ab) 56
CNS, sedative & hypnotics, 570
flupenthixole-alcohol (ab) 56
fluroxene toxicity-phenobarbital, 240
food and drugs, 8
gentamicin, inactivated by penicillins (ab) 718
halofenate-propranolol (ab) 472
hypnotics & sedatives, 570
mannitol-amphotericin B (ab) 472
Marcoumar®-Visken® (ab) 359
methadone-rifampin (ab) 473
nafcillin-sulfosalicylic acid (ab) 358
nitroglycerin-propranolol (ab) 358
oral contraceptives-plasma (ab) 184
pharmacokinetic, barbiturates, 571
phenylbutazone-tolbutamide (letter) 711
phenylephrine-nitroglycerin (ab) 125
plasma-oral contraceptives (ab) 184
prednisone-azathioprine (ab) 56
propranolol, halofenate (ab) 472; nitroglycerin (ab) 358
quinidine-anticonvulsant drugs (ab) 358
quinine-antipyrine (ab) 184
rifampin-methadone (ab) 473
sedatives & hypnotics, 570
smoking-theophylline (ab) 472
sulfisoxazole-warfarin (ab) 56
sulfosalicylic acid, nafcillin (ab) 358
theophylline-smoking (ab) 472
tolbutamide-phenylbutazone (letter) 711
urinary uric acid-ascorbic acid (ab) 472
Visken®-Marcoumar® (ab) 359
warfarin-sulfisoxazole (ab) 56
Drug, lag, 86; marketing, lag in, 86; monitoring, 258; prescribing, 321; product information disclosure (letter) 113; profiles, 274; promotion, 321; therapy, rational and nonrational, 258
Drug Management, of treatment-resistant depression (ab) 666
Drug Metabolism, of sedatives and hypnotics, 570
Drug Monitoring, antibiotic use control, 258
Drug Prescribing, studies on, 321; prescribing and drug ingestion, symbols and substances, 624
Drug Product Selection, enteric coatings, 588
Drugs, absorption and elimination of (ab) 359; and nutrition, 8; comments, digoxin, naloxone, 417; diseases and altered gastric emptying (ab), 664; error in guidelines for (letter) 417; guidelines for administration of, 206; increased knowledge base, 153; therapy, 339; solutions, 206
Drug Use, physicians' philosophy, 624
Drug Utilization Review, 222; antibiotic control, 258

E

Economics, drug utilization review, 222; relationship of price, setting & quality of services, 219
Editorials
David M. Angaran, Random Thoughts, 463
Paule Benfante, Advice to Young Students, 651
Alex Berman, Some Observations on the Report of the Study Commission on Pharmacy, 288
Angele D'Angelo, Special Strengths of the Woman Practitioner, 50
Robert P. Fischelis, Pharmacists for the Future, 347; Pharmacy and the Burger-Francke Syndrome, 592
Donald E. Francke, Abuse of Medicines, 51; American Board of Clinical Pharmacy, 180; Counseling the Patient, 416; Levels of Pharmacy Practice, 534; Pharmacists for the Future A Commentary on the Millis Report, 229; letter commenting on, 600; Pharmacy Administration as a Level of Pharmacy Practice, 710; Prescription for Pharmacy Practice 1984, 111; Roles for Pharmacy Practice, 593; The Pharmacotherapeutic Specialist, 651
Paul G. Pierpaoli, Needed: A New Value System for Upward Career Mobility In Hospital Pharmacy, 349
Dorothy L. Smith, The Patient Package Insert—Whose Responsibility?, 288
Ronald B. Stewart, The Team Approach to Decreasing Health Care Costs?, 709
Edward Superstine, The Significance and Importance of a "Drug-Free" Diagnosis, 111
John G. Wagner, Model-Independent Linear Pharmacokinetics, 179
H. A. K. Whitney, Jr., Pharmacy Isolationism, 463
Education and Training, See **Pharmaceutical Education**
Education, pharmaceutical, See **Pharmaceutical Education**
Elderly and Drug Consumption, 398
Electrolyte Therapy, 339
Emphysema and Chronic Bronchitis, 200
Enteric Coatings, 588; correction, Figures 1 and 2 must be reversed.
Enzyme Induction, interactions of barbiturates, 570
Enzymes, effects of drugs on, 8
Epidemiology of Disease, in detection of ADR (ab) 476
Epilepsy, use of clonazepam, 216
Epinephrine, In enflurane anesthesia, ventricular arrhythmias (ab) 57; in halothane anesthesia, ventricular arrhythmias (ab) 57
Errors, in dopamine letter, 351; in article by Madan, See **Madan;** in IV guidelines (letter) 418; in trace element article (letter) 466
Eshelman, Fred N. (editor) letter, use of povidone iodine in treatment of herpes, 116; (co-author) letter, death after propoxyphene overdose, 596
Estrogens and Endometrial Cancer (ab) 667
Estrogen, conjugated, endometrial carcinoma (ab) 185; endometrical carcinoma (ab) 185
Ethchlorvynol, pulmonary edema (ab) 239
European Public Health Community, Council of Europe, Working Party (authors) Abuse of Medicines, I. Self Medication, 16; II. Prescription Medicines, 94; III. General Recommendations, 172
Evans, William E. (co-author) Phenobarbital-Induced Hepatic Dysfunction, 439
Excretion barbiturates, 580; sulfadiazine, 402
Expectorants, in bronchitis & emphysema, 200
Extended Care Facilities, therapeutic problems, 703; role of clinical pharmacist, 268; Nurses' time with unit dose, 458

F

Faculty, clinical, 511; guidelines for Pharm.D., 409
Falck, Richard L. (author) Carbidopa and Levodopa - An Evaluation, 84; letter concerning the propranolol infusion rate - a correction, 233
Fallon, Jr., Joseph (author) letter concerning article on overdose with tricyclic antidepressants, 597
Farner, James (co-author) Impact of Drug Distribution Systems on Nurses' Time Involvement in Medication Related Activities in Long-Term Care Facilities, 458
Fast, J. H. (co-author) Reduced Bioavailability of Digoxin by Magnesium Perhydrol, 680
Fats, effects of drugs on, 8
Federation Internationale Pharmaceutique, 64th anniversary, 34; application for membership, 35; list of U.S. members, 36
Felice, June M. (author) letter of approval for Dr. Clinical series, 656
Fenbufen, analgesic value of (ab) 240
Filling of Syringes, 162
Fink, Joseph L. III (author) Child-Resistant Packaging for Medication, 698; (author) Some Legal Issues Presented in Clinical Pharmacy Practice, 444
Fischelis, Robert P. (ed.) Pharmacists for the Future, 347; (ed) Pharmacy and the Burger-Francke Syndrome, 592
Flucytosine, pharmacokinetics of (letter) 182
FluiDose II, method of filling syringes, 162
Fluid Therapy, 339
Flupenthixol and Amitriptyline, comparison of in outpatients (ab) 545
Flupenthixole, interaction with alcohol (ab) 56
Fluroxene Toxicity, interaction with phenobarbital (ab) 240
Food and Drugs, interactions, 8; interactions with sedatives, 570
Forni, Peter J. (co-author) letter, tricyclic antidepressant overdose, 711
Fortner, Clarence L. (co-author) a Benzquinamide-Induced Extrapyramidal Reaction, 638
Francke, Donald E. (ed) Abuse of Medicines, 51; American Board of Clinical Pharmacy, 180; Counseling the Patient, 416; Levels of Pharmacy Practice, 534; (co-author) Patterns of Clinical Pharmacy Education and Practice in the United States, 511; (ed) Pharmacists for the Future — A Commentary on the Millis Report, 229; Prescription for Pharmacy Practice 1984, 111; (ed) Pharmacy Administration as A Level of Pharmacy Practice, 710; (ed) Roles for Pharmacy Practice, 593; The Pharmacotherapeutic Specialist, 651
Franke, E. K. (co-author) A New Method for Quick Estimation of the Absorption Rate Constant for Clinical Purposes Using a Nomograph, 77
Fris, John M. (author) letter concerning patient compliance pilot program, 351
Furosemide, treatment of hypertension with (ab) 126

G

Gagnon, Jean P. (co-author) Results of a Preliminary Study of Consumer Attitudes on Hypertension Screening by Pharmacists, 283
Gentamicin, blood levels: a guide to nephrotoxicity (ab) 58; in children and adults, pharmacokinetics of (ab) 241; evaluation, 43; inactivated by penicillins (ab) 718; pharmacokinetics of (ab) 544; predictability of blood levels of (ab) 126; kinetics of dosing regimens which utilize multiple IV infusions (ab) 609; acute renal failure, 716
Gever, Larry N. (author) letter, authority of the clinical pharmacist, 657
Giorgianni, Salvatore J., Jr. (author) letter apologizing for error in his letter on dopamine, 351
Giusti, Donald L. (co-author) letter thanking colleague for corrected error in article, 183
Goldstein, George S. (author) letter, removal of tartrazine from the open market, 652
Gollamudi, Ramachander (author) book review, 661
Goodman, Maxine E. (author) letter praising Dr. Clinical, 713
Gotz, Vincent P. (co-author) Beclomethasone Dipropionate Evaluation, 635; (author) Penicillin Desensitization—A Case Review, 333

Graham, Gary Lee (author) letter, continuing education seminar in California, 351
Grant, Kathryn (co-author) Guidelines for the Administration of Commonly Used IV Drugs - An Update, 206; letter concerning the authors' comments on a critique of their article, 418; letter concerning error in her article about IV guidelines, 418
Greenberg, Barbara (author) abstract, 126, 360
Grossman, James Bernard (author) letter, patient's resistance to digoxin and hyperthyroidism, 654
Grossman, Joshua Bernard (author) letter, three separate cases of digitalis-induced cardiac arrhythmias, 467
Grove, William R. (co-author) A Benzquinamide-Induced Extrapyramidal Reaction - Case Study, 638
Guidelines, 206; for authors, 15; for IV drugs, 206 (letter) 417; for Pharm.D. programs, 409

H

Hafner, Dina (author) letter, use of trimethoprim-sulfamethoxazole for the treatment of pneumocystis carinii in children, 290
Hak, Sandra H. (co-author) Overdoses With Tricyclic Antidepressants - Two Case Reports, 380
Halofenate, Clofibrate, and Placebo, trials with (ab) 425
Halofenate, interaction with propranolol (ab) 472
Hamilton, Beverly (co-author) letter, interaction between antacid and nitrofurantoin, 419
Hamilton, Stephen F. (author) Therapeutic Problems and Nursing Home Patients, 703
Harsfield, Jeffrey C. (co-author) letter comparing propoxyphene hydrochloride vs. napsylate salt, 53
Hartshorn, Edward A. (author) book review, 714; (co-author) Interactions of CNS Drugs—Hypnotics and Sedatives, 570; (author) letter responding to comment on antipsychotic drug article, 54
Hays, Dennis (co-author) letter, overdose with tricyclic antidepressants, 600
Health Care Costs, team approach (ed) 709
Health Care Sociology
alcohol consumption, economic changes (ab) 353
cigarette smoke, irritation in man (ab) 709
contraceptives, oral, distribution of (ab) 708
deaths, coronary disease and coffee (ab) 707
drug abuse, computers aid control of (ab) 120
drugs, administration of, to elderly (ab) 236
drug prescribing, hospitals (ab) 708
emergencies, medical, response to (ab) 353
injuries, to research subjects (ab) 709
nurse practitioners, independent behavior of (ab) 708
pharmacy, report of study commission on (ab) 119
pharmacy services, incidence of, short-term hospitals (ab) 353
primary care, medical, quality of (ab) 237; in a penal institution (ab) 236
swine-influenza decision (ab) 708
tobacco smoke, in public places (ab) 236
urban dogs, public health implications (ab) 237
Health Care Narrow Vision Attacked (letter) 116
Health Insurance, prescription benefits, 529
Hemminki, Elina (author) Factors Influencing Drug Prescribing—Inquiry into Research Strategy, 321
Heparin, thrombocytopenia (ab) 546
Hepatic Dysfunction, phenobarbital induced, 439
Hepatitis, methyldopa, 144
Hepatotoxicity, & leukopenia 562
Herpes, treatment with povidone iodine (letter) 116; vidarabine (ab) 426
Hexamethylmelamine, investigational information, 48
Heyndrickx, A., Professor (author) letter, forensic toxicologists symposium to be held in Belgium, 294
Hicks, Charles I. (author) letter, 9th Annual Hospital Pharmacy Seminar of the University of Toledo College of Pharmacy, 540; (co-author) The Impact of Drug Distribution Systems on Nurses' Time Involvement in Medication Related Activities in Long-Term Care Facilities, 458
History, clinical pharmacy, 506; drug use, 624; timeless need (letter) 655
Hoffman, Richard P. (co-author) Trace Element Concentrations in Commercially Available Solutions, 74
Honorary Degrees—Does Pharmacy Need Them? (letter) 114
Hormones Psychoactive: Evoked Potential Investigations (ab) 59
Horn, John R. (author) book review, 471, 542; (co-author) letter thanking colleague who corrected error in article, 183
Hospital Pharmacy, a new value system for upward career mobility needed (ed) 346
Houtz, Ardith (editor) letter, low opinion of health care, 116
Hutchinson, Richard A. (co-author) Evaluation of the Utilization of Medication Profiles for the Purpose of Drug-Drug Interaction Surveillance by Pharmacists in a Community Setting, 274; letter, hospital pharmacists compounding accuracy, 465; (co-author) letter, medication profiles in a community setting, 606
Hydergine, sinus bradycardia (ab) 185
25-Hydroxycholecalciferol, in chronic renal disease (ab) 126
Hyperalimentation Solutions, 684; trace minerals, 74; IV fat emulsion (ab) 184
Hypertension, benign intracranial, 566
Hypertension Screening, 283; role of allied health professions (letter) 653
Hypnotics, drug interactions, 570

I

Imipramine, overdose with, 380
Immunosuppressive Therapy, of Factor VIII inhibitors (ab) 666
Indoramin, pharmacokinetics of (ab) 609
Influenza A/England/42/72 (H3N2) Vaccine (Alice) (ab) 297
Information, patient vs. patient education, 314
Insulin Adsorption Controversy (letter) 232
International Pharmaceutical Federation, 64th anniversary, 34; application for membership, 35; list of U.S. members, 36
International Symposium on Drug Activity (letter) 541
Intravenous, drug abuse, serratia marcescens endocarditis (ab) 239; guidelines, 260
Intrinsic Factor, spurious results with (ab) 185
Investigational Drug Information, Carmustine, 49; Dacarbazine, 48; Hexamethylmelamine, 48
Isoniazid, new, for fast metabolizers (ab) 59
Ivey, Marianne F. (author) book review, 659

J

Jackson, Eric A. (author) book review, 470
Jaffe, James M. (co-author) letter, interaction between antacid and nitrofurantoin, 419
Jeffers, Sheryl (co-author) letter, interaction between antacid and nitrofurantoin, 419
Jeffery, William H. (author) letter, correction in phenobarbital-induced hepatic dysfunction letter, 654
Jones, Mark E. (author) book review, 422, 469; (co-author) letter, pharmacokinetics of flucytosine, 182
Jones, William N. (author) letter, value of B.Sc. pharmacists, 113
Jue, Sandra G. (co-author) letter, tolbutamide-phenylbutazone interaction, 711; (author) letter giving case of desipramine poisoning, 52

K

Kanamycin, dosage in children, pharmacokinetics compared with amikacin (ab) 717
Kane, Robert L. (co-author) The role of the Clinical Pharmacist on a Nursing Home Care Team, 268
Kaul, Alan F. (co-author) letter comparing propoxyphene hydrochloride vs. napsylate salt, 53
Kavula, Michael P., Jr. (author) book review, 714
Ketamine, effects of during halothane and enflurane anesthesia (ab) 59
Kehrer, James P. (author) letter commenting on article about future pharmacy practice, 55
Kikugawa, Cynthia A. (co-author) letter, overdose with tricyclic antidepressants, 600
Kleinman, Larry M. (co-editor) Investigational Drug Information, 48
Klimek, Joseph J. (co-author) letter, comparative costs of two cephalosporins, cefazolin and cephalothin, 655
Knapp, David A. (author) A Case for Two Professional Degree Programs in Pharmacy, 330; letter replying to comments on a previous letter of his, 537
Knoben, James E. (author) Drug Utilization Review — Current Status and Relationship to Assuring Quality Medical Care, 222; (co-author) Physician Prescribing Patterns — Therapeutic Categories and Age Considerations, 398
Kohlberg, Joshua (author) letter informing readers about international symposium on drug activity, 541
Kotabe, Sharonlee E. (co-author) letter, overdose with tricyclic antidepressants, 600
Koup, Jeffrey R. (author) letter congratulating authors about article on absorption rate constant calculation techniques, 350; (co-author) Fluctuations of Serum Phenobarbital and Phenytoin Concentrations During Two Acute Episodes of Diabetic Ketoacidosis — Report of a Case, 436
Kramer, Warren (author) book review, 189
Kuhn, John (co-author) letter concerning IV infusion of naloxone, 417

L

Labetalol, alpha- and beta-adrenoceptor blockade with (ab) 545; pharmacology in man (ab) 717
Laboratory Values, effect of barbiturates on, 570
LaCorte, Mary F. (author) letter, medical-legal dangers in the use of Wycillin® syringes, 418
Lamy, Peter P. (co-author) The Pediatric Medical Triangle, 498
Lauper, R. David (co-author) Beclomethasone Dipropionate Evaluation, 635
Laventurier, Marc (author), confusion about title of Pharm.D. (let me call you doctor) 294
Legal Issues, clinical pharmacy, 444
Legislation and Drug Lag, 86
Let Me Call You Doctor (letter) 294
Letters to the Editor
absorption rate nomogram, 350; Professor Ritschel's reply, 351
American board of clinical pharmacy, 292, 419
ampules, value of filtering, 293
anti-human lymphocyte globulin - heparin precipitate, 654
antipsychotic, drug article, 294; drug interaction, 114; drugs, 54
authority of the clinical pharmacist, 657
board certification, clinical pharmacy, 349; board certification, 349; Gregory Thompson's reply, 350
B.Sc. pharmacists, value of, 113
calcitonin-salmon in multiple myeloma induced hypercalcemia, 52
carbidopa and levodopa, comment on, 290
clinical pharmacy, board certification, 349; Gregory Thompson's reply, 350; cost benefits of, 181; in a psychiatric hospital, 466, 653; role pioneering, 655
clinical scientist concept, 601
comparative costs of two cephalosporins, cefazolin and cephalothin, 655
compounding accuracy of hospital pharmacists, 465
continuing education in California, 351
controversy about insulin adsorption, 232
correction to trace element article, 466
death, propoxyphene overdose, 596
desipramine, accidental poisoning, 52
DIA 12th annual meeting, 294
digitalis-induced cardiac arrhythmias, 467
digoxin, and hyperthyroidism resistance, 654; slow IV infusion, 417
Dr. Clinical, comments on series, 656; out of place, 536; stimulates, 656
dopamine dosage, 183
drug interaction, antipsychotic, 114
drug product information disclosure, 113
error in dopamine letter, 351; in IV guidelines article, 418
evaluation of drug interactions, 233
flucytosine, pharmacokinetics, 182; author's appreciation (letter) 183
forensic toxicologists, 294
herpes, treatment with povidone iodine, 116
history, 655
honorary degrees, pharmacy's need for them, 114
international symposium on drug activity, 541
IV drugs, guidelines for, 417
let me call you doctor, 294
levels of pharmacy practice, 713
levodopa and carbidopa, comment on, 290
literature search on patient compliance, 537
medication profiles in a community setting, 606; author's reply, 606
metabolic alkalosis and hydrochloric acid, 231
naloxone — IV infusion, 417
narrow vision of health care attacked, 116
need for federal control of plumbism (lead poisoning) 231
new drug products, 182
nitrofurantoin-antacid interaction, 419
organization of Univ. of Michigan Hospital Pharmacy Alumni Association, 234
overdose, tricyclic antidepressants, 597; 652; 711
patient compliance, 115; aids, 541; pilot program, 351
penicillin skin testing, 540
pharmacists for the future, 600
pharmacy isolationism, 657
pharmacy practice in the year 2000, 55
Pharm.D., plagiarism by, 293; 466; continued, 536
phenobarbital-induced hepatic dysfunction, 654
plagiarism by Pharm.D., 293; 466; continued, 536

plumbism (lead poisoning) - need for federal control, 231
pneumocystis carinii in children, trimethoprim-sulfamethoxazole for, 290
programs, two professional degrees, 537; author's reply, 537
propoxyphene hydrochloride, vs. napsylate salt, 53; overdose, death, 596
propranolol infusion rate - correction, 233
povidone iodine, used in treatment of herpes, 116
public OTC drug instruction, 467
role of the allied health professions, 653
small volume unit/dose packaging, 467
sulfadiazine bioavailability, 606
symposium, of toxicological information, 290
tartrazine, 652; revisited, 351; update, 606
tolbutamide-phenylbutazone interaction, 711
Toledo annual seminar, 540
tricyclic antidepressants, 600; overdose, 597; overdose, 711
trimethoprim-sulfamethoxazole for pneumocystis carinii in children, 290
use of medication profiles, 540
value of filtering ampules, 293
Wycillin syringes, dangers in use of, 418; reply to, 605
Leukopenia, & hepatotoxicity, 562
Levels of Pharmacy Practice (ed) 534
Levodopa and Carbidopa, comment on (letter) 290
Levodopa, carbidopa, evaluation, 84; five years later (ab) 125; therapy, long-term thrombocytopenia (ab) 476
Levy, Gerhard (author) book review, 660
Lewis, Earl T. (author) letter replying to comments about Wycillin syringes, 605
Lewis, JoAnn (author) letter, value of filtering ampuls, 293
Libby, G. Neil (author) letter, misconception of Pharm.D. title, 293
Likes, Keith E. (co-author) letter, death after propoxyphene overdose, 596
Literature, 121, 188, 295, 356, 421, 469, 542, 659, 714
Literature Search on Patient Compliance (letter) 537
Lithium, irreversible inhibition of chlorine transport system (ab) 607
Liver, phenobarbital-induced hepatic dysfunction, 439
Long-Term Care Facilities, See **Extended Care Facilities**
Long, Walter J. (author) letter, sulfadiazine bioavailability, 606
Love, N. Carolyn (co-author) The Pediatric Medical Triangle, 498
Ludy, Judith A. (co-author) Overdoses With Tricyclic Antidepressants - Two Case Reports, 380
Lunde, J. E. (co-author) Reduced Bioavailability of Digoxin by Magnesium Perhydrol, 680
Lundin, Sharon (author) poem about clinical pharmacy role pioneering, 655
Lung, neoplasms, diagnosis of cough, 640

M

Madan, Devendra K. (co-author) Total Parenteral Nutrition, 684
Madan, Parshotam L. (co-author) Total Parenteral Nutrition, 684; (co-author) In-Vitro Determination of the Resistance of Commercial Enteric-Coating to Acidic Conditions, 588; Correction, Figures 1 and 2 must be reversed; (author) letter, deHaen new drug products, 182; letter, need for federal control on the amount of lead in certain items, 231
Magnesium Perhydrol, reduced digoxin bioavailability, 680
Mahoney, Dennis (co-author) Evaluation of the Utilization of Medication Profiles for the Purpose of Drug-Drug Interaction Surveillance by Pharmacists in a Community Setting, 274
Mannitol, interaction with amphotericin B (ab) 472
Mantsch, Michael (author) letter about treatment of multiple myeloma induced hypercalcemia with calcitonin-salmon, 52; (co-author) Fluidose II - A Semi-automatic Method Used in Filling Unit-of-Use Syringes, 162
Manuscripts, author's guidelines, 15
Marcoumar®, interaction with Visken® (ab) 359
Marder, Joseph E. (author) letter, antipsychotic drug article, 54
Market Rating of Drugs, 86
Marshall, William R. (co-author) Overdose With Tricyclic Antidepressants - Two Case Reports, 380
Martin, David J. (author) letter, metabolic alkalosis and the effect hydrochloric acid has on it, 231
McCoy, Linda K. (author) book review, 470
McLeod, Don C. (editor) Drug Evaluation Data, 43, 84, 216, 635
Medicaid Program, 529
Medical Care, primary, quality of (ab) 237
Medication, child-resistant packaging, 698; data sheets, 448
Medication Profiles, 274; use (letter) 540; data sheets, 448; in a community setting (letter) 606
Medication Regimens, 386
Medicines, abuse of (ed) 51; recommendations to control abuse, 16, 94, 172
Meinhold, Jane M. (co-editor) Drug Evaluation Data, 216
Meningococcal Disease, management of (ab) 241
Metabolic Alkalosis, and hydrochloric acid (letter) 231
Metals, effects of drugs on, 8
Methadone, interaction with rifampin (ab) 473; side effects (ab) 716
Methotrimeprazine, pharmacokinetics of (ab) 426
Methyldopa, effects of on prolactin and growth hormone (ab) 608; hepatitis, 144; withdrawal, rebound hypertension (ab) 476
Methylphenidate Hydrochloride, tics in children (ab) 359
Millis Report, Pharmacists For The Future (summary) 119; 229; 347, 600; the cynic commission, 394
Minerals in Parenteral Solutions, 74
Minisci, Marie (co-author) In-Vitro Determination of the Resistance of Commercial Enteric-Coating to Acidic Conditions, 588
Minocycline, dizziness (ab) 607; vertigo (ab) 607; ataxia (ab) 607; weakness (ab) 607; nausea (ab) 607; vomiting (ab) 607
Minoxidil, treatment of hypertension with (ab) 126
Model, systems for medicines in society, 16; 172
Model-Independent Linear Pharmacokinetics (ed) 179
Monoamine Oxidase Inhibitors, agranulocytosis (ab) 667
Morphine, kinetics of high-dose IV (ab) 477
Murray, William (author) letter, misinformation about length of pharmacy programs, 537
Mutchie, Kelly D. (co-editor) Drug Evaluation Data, 216

N

Nafcillin, interaction with sulfosalicylic acid (ab) 358
Nalidixic Acid, pseudotumor cerebri, 566
Naloxone – IV Infusion (letter) 417
Nappi, Jean (co-author) letter, IV infusion of Naloxone, 417
Naproxen and Aspirin, in rheumatoid arthritis (ab) 666
National Health Insurance, 529
Nelson, Arthur A., Jr. (co-author) Evaluation of the Utilization of Medication Profiles for the Purpose of Drug-Drug Interaction Surveillance by Pharmacists in a Community Setting, 274; letter, hospital pharmacists compounding accuracy, 465; (co-author) letter, medication profiles in a community setting, 606
New Antiinflammatory Drugs, evaluation of (ab) 544
New Drugs, time of marketing, 86
New Products (drug) (letter) 182
Nitrofurantoin-Antacid Interaction (letter) 419
Nitroglycerin, interaction with phenylephrine (ab) 125; interaction with propranolol (ab) 358; hypotension (ab) 716
Nomograms, absorption rate constant, 77
Noncompliance, in pediatric patients, 498
Nordiazepam, and potassium clorazepate, effect on sleep (ab) 718
Nowacki, Bibiana C. (author) letter, shortcomings of meeting of allied health professionals on hypertension, 653
Nurses, compounding by, legal issues, 444; time involvement in medications with unit dose, 458
Nursing Home Care Team, 268
Nursing Homes, See **Extended Care Facilities**
Nutrition, effects of drugs on, 8; total parenteral, 684; IV fat emulsion (ab) 186; trace minerals, 74

O

Ogbuokiri, Justina E. (author) abstract, 240
Ogzewalla, C. Dwayne (author) book review, 422
Oral Antidiabetic Drugs and Diet (ab) 425
Oral Contraceptives, carbohydrate tolerance, changes in (ab) 57; gallbladder disease (ab) 296; interaction with plasma (ab) 184
Osmolak, Barbara (co-author) letter, hospital pharmacists compounding accuracy, 465
Overdose, see **Adverse Drug Reactions**
Oxazepam, disposition of in viral hepatitis and cirrhosis (ab) 476
Oxprenolol, oral, circulatory collapse (ab) 124

P

Packaging, child-resistant, 698
Palmieri III, Anthony (author) letter disapproving of Dr. Clinical series, 656
Palumbo, Joseph F. (co-author) Total Parenteral Nutrition, 684
Pancreatic Extract, high dose, hyperuricosuria (ab) 546
Parascandola, John (author of introduction) Clinical Pharmacy in Historical Perspective, 505
Parent-Child Relationship, 498
Parenteral Nutrition, 684, IV fat emulsion (ab) 186; trace minerals, 74
Parenteral Solutions, filling syringes, 162; filtering ampuls, 288; fluid & electrolyte therapy, 339; IV guidelines, 206; trace minerals, 74
Patient, self-administration of medicines, 448
Patient Care, computers used to improve, (ab) 120
Patient Compliance, 386
aids (letter), 541
bibliography, 314; 318
with dosage regimens, 500
factors in noncompliance, 499
literature search, 537
patient information vs. education, 314
pilot program (letter) 351, 448
system (letter) 115
Patient Consent, legal issues, 444
Patient Counseling
bronchitis & emphysema patients, 200
community pharmacists, 274; (letter) 540
cough medication, 640
editorial, 409
medication data sheets, 448
patient education, 314
relationship to practice setting, 219
Patient Drug History, importance of a "drug-free" diagnosis (ed) 111
Patient Education vs. information, 314; compliance, 386; medication data sheets, 448; OTC instruction (letter) 467; patient package insert, 288
Patient Monitoring, 448; community pharmacists, 274; (letter) 606; medication data sheets, 448
Patient Package Insert—Whose Responsibility? (editorial) 288
Patient-Physician Communication, 498
Patient Profiles, 448; in community and hospital practice, 540
Patients, nursing home, therapeutic problems, 703
Paulson, Margaret Lamont (co-author) Medication Data Sheets – An Aid to Patient Education, 448
Paulson, Patrick Thomas (co-author) Medication Data Sheets – An Aid to Patient Education, 448
Pediatric, case study, pseudotumor cerebri, 566 medical triangle, 498
Pellegrino, Edmund D. (author) Prescribing and Drug Ingestion Symbols and Substances, 624
Penicillin Allergy, 333
Penicillin Desensitization, a case study, 333
Penicillin Skin Testing, 333; (letter) 540
Penta, John S. (co-editor) Investigational Drug Information, 48
Pentazocine, iatrogenic muscle fibrosis (ab) 124; psychosis (ab) 57
Phaff, Harry (author) letter, certification of clinical pharmacy board, 349
Pharmaceutical Education
impact of clinical pharmacy on curriculum, 522; levels of pharmacy practice (ed) 534; maturing, Pharm.D. ripe, 153; patterns of clinical pharmacy, 511; Pharm.D. guidelines, 409; two professional degrees, 330
Pharmacists for the Future – A Commentary on the Millis Report (ed) 229; (ab) 119; 347; the Cynic Commission, 394; letter, 600
Pharmacists' Roles, consultant, 330, 331, 506; for pharmacy practice (ed) 593; hypertension screening, 283
Pharmacokinetics, 570
absorption rate constant, 77
acetaminophen (ab) 425; effect of dialysis on (ab) 241
amikacin (ab) 546
anticonvulsants (ab) 608
cefamandole, 298
cefamandole, cephapirin & cephalothin, compared (ab) 718
cefazolin (ab) 525; (ab) 718
cefuroxime (ab) 477
cephalothin (ab) 718
cephradine (ab) 717
clonidine (ab) 298
computer program (ab) 359
doxycycline, 666
gentamicin, 43; (ab) 58; (ab) 126; (ab) 241; (ab) 544; (ab) IV, 609; (ab) 716
of flucytosine (letter) 182
indoramin (ab) 609
interaction of barbiturates, 570
kanamycin (ab) 717
linear, model-independent (ed) 179
methotrimeprazine, 426

morphine (ab) 477
pivampicillin (ab) 58
quinidine (ab) 126
sisomicin (ab) 477
sulfamethoxazole (ab) 359
tobramycin, 43
tocainide (ab) 545
tolamolol (ab) 125
Pharmacy, Burger-Francke syndrome (ed) 592; hospital, career mobility in, (ed) 346; isolationism (ed) 463, (letter) 657; observations on report of the study commission (ed) 288; report by the study commission (ab) 119
Pharmacy Practice, 219; administration as a level of (ed) 710; in the year 2000 (letter) 55; 1984, prescription for (ed) 111; levels of (editorial) 534; (letter) 713; practice setting, 219
Pharmacy and Therapeutics Committee, role in antibiotic control, 258
Pharmacy Services, incidence of, ASHP survey (ab) 353; price and practice setting of, 219
Pharmacy Students, strike by, 651
Pharm.D., plagiarism by (letter) 293, 466, 536; guidelines for programs, 409
Phenobarbital, 436, 439; induced hepatic dysfunction (letter) 654; interaction with fluroxene toxicity (ab) 240; osteomalacia (ab) 239
Phenothiazine, agranulocytosis (ab) 667; case study, 562
Phenylbutazone, interaction with tolbutamide (letter) 711
Phenylephrine, interaction with nitroglycerin (ab) 125
Phenytoin, 436; oral and intramuscular (ab) 425; osteomalacia (ab) 239
Physicians and Compliance, 386
Physostigmine, antidote for tricyclic antidepressants, 380
Piecoro, John J., Jr. (co-author) Guidelines for the Administration of Commonly Used Intravenous Drugs – An Update, 206; letter, error in article about IV guidelines, 418; letter concerning the authors' comments on a critique of their article, 418
Pierpaoli, Paul G. (co-author) Antibiotic use Control – An Institutional Model, 258; (ed) Needed: A New Value System for Upward Career Mobility in Hospital Pharmacy, 346
Pietrusko, Robert G. (author) book review, 188
Pivampicillin, absorption of (ab) 58
Placebo, halofenate, and clofibrate, trials with (ab) 425
Plagiarism, by Pharm.D. (letters) 293, 466, 536
Plasma, interaction with oral contraceptives (ab) 184
Plumbism – need for Federal control (letter) 231
Pneumocystis carinii in Children, trimethoprim-sulfamethoxazole for (letter) 290
Poisoning, 380; camphor, 631; (ab) 359; See also **Adverse Drug Reactions**
Ponte, Charles D. (co-author) Leukopenia and Hepatotoxicity as a Possible Consequence of Chlorpromazine Administration, 562
Pothier, P. E. (author) Patient Compliance in Therapy, 314
Povidone Iodine, used in treatment of herpes (letter) 116
Prazosin, for hypertension (ab) 296; in management of hypertension (ab) 240
Prednisone, in diffuse lupus nephritis (ab) 664; tablets, 8 commercial, comparative bioavailability (ab) 666; interaction with azathioprine (ab) 56
Prescribing, factors influencing, studies, 321; rational & drug utilization review, 222, physicians prescribing patterns, 398; pharmacists as advisors to, 331; philosophy, 624
Prescription Benefits, under health insurance, 529
Prescription for Pharmacy Practice 1984 (ed) 111
Prescription Medicines, 94
Primary Care, clinical pharmacy, 506; in a penal institution (ab) 236
Price, practice setting, quality of pharmaceutical services, 219. See also **Cost**
Prince, Randall A. (co-author) letter, pharmacokinetics of flucytosine, 182
Professional Services of Pharmacist, 331, 506
Propoxyphene, hydrochloride vs. napsylate salt (letter) 53; and propranolol, disposition of (ab) 425
Propranolol, infusion rate (letter) 233; interaction with halofenate (ab) 472; interaction with nitroglycerin (ab) 358; propoxyphene, disposition of (ab) 425; psoriasiform cutaneous eruptions (ab) 608; treatment of hypertension with (ab) 126
Proteins, effects of drugs on, 8
Protocols for Antibiotic Use, 258; legal issues, 444
Prus, Richard M. (author) letter complaining about Dr. Clinical articles, 536
Pseudotumor Cerebri, associated with drug therapy, 566
Psychotherapeutic Control of Hypertension (ab) 186

Q

Quality, assurance, 222; of pharmaceutical services, 219; of primary medical care (ab) 237
Quinidine, interaction with anticonvulsant drugs (ab) 358
Quinine, interaction with antipyrine (ab) 184
Quintilliani, Richard (co-author) letter, comparative costs of two cephalosporins, cefazolin and cephalothin, 655

R

Random Thoughts (ed) 463
Rapp, Robert P. (co-author) Guidelines for the Administration of Commonly Used IV Drugs – An Update, 206; letter, authors' comments on a critique of their article, 418; letter, error in his article about IV guidelines, 418
Rational Prescribing, 624; fluids & electrolytes, 339
Referees for 1976, 720
Report of the Study Commission on Pharmacy (ab) 119; See also **Millis Report**
Residency Programs, 511
Response to Medical Emergencies (ab) 353
Rifampin, interaction with methadone (ab) 473
Riley, N. Arthur (co-author) The Pediatric Medical Triangle, 498
Ringstrom, James (co-author) Evaluation of the Utilization of Medication Profiles for the Purpose of Drug-Drug Interaction Surveillance by Pharmacists in a Community Setting, 274
Ritschel, G. (co-author) Study on Bioavailability of Sulfadiazine Tablets in Man, 402
Ritschel, W. A. (author) letter reply to comments on article, 351; (co-author) A New Method for Quick Estimation of the Absorption Rate Constant for Clinical Purposes Using a Nomograph, 77; Study on Bioavailability of Sulfadiazine Tablets in Man, 402; (author) book review, 715; (author) letter, reply to comments about his article on sulfadiazine bioavailability, 606
Roach, Albert C. (author) letter, two errors in tricyclic antidepressants overdose article, 652
Roberts, Rosemary (co-author) Overdoses With Tricyclic Antidepressants – Two Case Reports, 380
Robinson, J. Daniel (author) book review, 421
Rodowskas, Christopher A., Jr. (author) Impact of Clinical Pharmacy on the Curriculum, 522
Role of the Allied Health Professions (letter) 653
Rosencrance, John (author) letter, patient compliance pilot program, 351
Rotmensch, J. (co-author) Study on Bioavailability of Sulfadiazine Tablets in Man, 402
Rowles, Brandt (co-author) Relationship of Price, Practice Setting and Quality of Pharmaceutical Services, 219
Rucker, T. Donald (author) National Health Insurance and Prescription Benefits, 529
Rupp, Claudia A. (co-author) letter about overdose with tricyclic antidepressants, 600

S

Salbutamol, IV infusion of (ab) 424
Scalley, Robert D. (author) letter, concerning Pharm.D.'s, 536
Scheuer, Caryl L. (co-author) letter, methods of finding information on patient compliance, 537
Schwartz, Ronald A. (author) letter, incorrect dopamine dosage, 183
Sedatives, drug interactions, 570
Self, Timothy H. (co-author) Phenobarbital-Induced Hepatic Dysfunction, 439
Self-Medication, 16; medication data sheets, value, 448
Sensitization, penicillin de-, 333; (letter) 540
Serum Albumin, binding of drugs to (ab) 298
Shearer, Cameron A. (author) abstracts, 57, 126, 296, 297, 542; letter, correction in the Trace Element article, 466
Sherrin, Thomas P. (co-author) Fluidose II – A Semi-Automatic Method Used in Filling Unit-of-Use Syringes, 162
Sinotte, L. Paul (author) letter containing list of extra products left out of article, 351
Sisomicin Dosage Schedules, in renal-impairment (ab) 477
Skaggs, Charles O. (author) letter, small volume unit/dose packaging, 467
Slavik, Milan (co-editor) Investigational Drug Information, 48
Sleep, effects of nordiazepam and potassium clorazepate (ab) 718
Sliwoski, Mike (co-author) letter, hospital pharmacists compounding accuracy, 465
Smith, Dorothy L. (author) Patient Compliance With Medication Regimens, 386; (ed) The Patient Package Insert – Whose Responsibility?, 288
Smith, William E. (author) letter, pharmacists for the future, 600
Smoking, interaction with theophylline (ab) 472
Smooth Muscle Antibody, in heroin addicts (ab) 186
Snodgrass, Gary L. (author) letter, creation of an American Board of Clinical Pharmacy, 292
Social Aspects of Drug Ingestion, 624
Sodium Cromoglycate, in chronic asthma (ab) 424
Sodium Fluoride and Calcium Carbonate, multiple-myeloma bone disease: effect of (ab) 298
Sodium Salicylate, 588; correction, Figures 1 and 2 must be reversed.
Spears, Jeffrey B. (author) abstracts, 58, 126
Speir, William A., Jr. (author) Chronic Obstructive Lung Disease – Chronic Bronchitis and Emphysema, 200
Spigiel, Robert W. (co-author) Implications of Camphor Poisoning – Therapeutic and Administrative, 631
Stach, Paul E. (co-author) Fluidose II – A Semi-Automatic Method Used in Filling Unit-of-Use Syringes, 162
Stead, Ken (co-author) letter, drug used in post kidney transplant, 654
Sterility, syringes, 162
Stewart, Ronald B. (ed) The Team Approach to Decreasing Health Care Costs, 709
Stimmel, Glen L. (author) letter, authors negative attitude towards the organization of an independent American Board of Clinical Pharmacy, 419
Strauss, Gary (co-author) A Benzquinamide-Induced Extrapyramidal Reaction, 638
Stuart, David M. (author) letter, cost benefits of clinical pharmacy, 181
Sulfadiazine, bioavailability, 402; (letter) 606
Sulfisoxazole, interaction with warfarin (ab) 56; pharmacokinetics of (ab) 359
Sulfosalicylic Acid, interaction with nafcillin (ab) 358
Superstine, Edward (ed) The Significance and Importance of a "Drug-Free" Diagnosis, 111
Swintosky, Joseph V. (author) Maturing of Pharmaceutical Education, 153
Symbolism, in drug prescribing and use, 624
Syringes, filling, by Fluidose, 162; dangers in use of Wycillin®, 418

T

Tablets, sodium salicylate, 588; sulfadiazine, bioavailability, 402
Tartrazine (letter) 606; (letter) 652; revisited (letter) 351
Taylor, William J., Jr. (co-editor) Drug Evaluation Data, 216
Tetracycline, pseudotumor cerebri, 566
Theophylline, interaction with smoking (ab) 472
Therapeutics, physicians' philosophy, 624
Therapy Problems, of nursing home patients, 703
Thiamphenicol, peritoneal transfer of (ab) 477
Thioridazine, agranulocytosis (ab) 667
Thompson, Gregory A. (author) Board Certification for Clinical Pharmacy, 168; letter replying to comments made about an article he wrote, 350
Ticarcillin, in gram-negative infections (ab) 360
Tilton, Richard C. (co-author) Antibiotic Use Control—An Institutional Model, 258
Time Study, filling syringes, 162
Tobacco Smoke, in public places (ab) 236; (ab) 472
Tobramycin, evaluation, 43
Tocainide, kinetics of (ab) 545
Tolamolol, pharmacokinetics of (ab) 125
Tolbutamide, interaction with phenylbutazone (letter) 711
Toledo Annual Seminar (letter) 540
Tong, Theodore G. (co-author) letter, tricyclic antidepressant overdose, 711
Toxicity, tricyclic antidepressants, 380
Toxicological Information Symposium (ed) 290
Toxicologists, Forensic (letter) 294
Trace Elements, in parenteral solutions, 74; contamination of IV solutions (ab) 664
Triamcinolone, aerosol for asthma (ab) 424
Tricyclic Antidepressants, overdose, 380; (letter) 600; memory difficulty (ab) 667; overdose (letter) 711; poisoning, coma (ab) 607; systolic blood pressure (ab) 607
Trimethaphan Camsylate, respiratory paralysis (ab) 607
Trimethoprim-Sulfamethoxazole, amoxicillin, comparison of (ab) 241; for pneumocystis carinii in children (letter) 290

Trudeau, Terry W. (author) letter, levels of pharmacy practice, 713
Tse, Teddy C. S. (author) abstract, 424

U

Unit Dose Packaging, influence on nursing time in long care facility, 458; small volume (letter) 467; syringes, 162
University of Michigan Hospital Pharmacy Alumni Association (letter) 234
Urinary Uric Acid, interaction with ascorbic acid (ab) 472

V

van der Vijgh, W. J. F. (co-author) Reduced Bioavailability of Digoxin by Magnesium Perhydrol, 680
Varano, Carmine (author) letter, certification of clinical pharmacy board, 349; letter, questionable need of honorary degrees in pharmacy, 114
Vidarabine, for herpesvirus infections (ab) 426
Vinall, James R. (author) letter, acceptability of Pharm.D. program, 466
Visken®, interaction with Marcoumar® (ab) 359
Vitamin A, pseudotumor cerebri, 566
Vitamins, effects of drugs on, 8

W

Wagner, John G. (ed) Model-Independent Linear Pharmacokinetics, 179
Wareham, Darryl V. (co-author) Rational Fluid and Electrolyte Therapy Utilization Review — Part I, 339
Warfarin Elimination, serum protein binding as a determinant of (ab) 544
Warfarin, interaction with sulfisoxazole (ab) 56
Water, electrolytes, effects of drugs on, 8
Weber, Charles E. (author) letter concerning slow infusion of digoxin in IV, 417
Wehrle, Sandra E. (author) letter, medication profiles in community pharmacy and institutional pharmacy, 540
Weiner, Bruce (author) letter thanking author of antipsychotic drug article, 294
Weisburst, Mark R. (co-author) Phenobarbital-Induced Hepatic Dysfunction, 439
Wertheimer, Albert I. (co-author) Physician Prescribing Patterns — Therapeutic Categories and Age Considerations, 398; The Relationship of Price, Practice Setting and Quality of Pharmaceutical Services, 219
Whitney, Harvey A. K., Jr. (co-author) Patterns of Clinical Pharmacy Education and Practice in the United States, 511; (ed) Pharmacy Isolationism, 463
Wiernik, Peter H. (co-author) A Benzquinamide-Induced Extrapyramidal Reaction, 638
Women in Pharmacy, special strengths (ed) 50
Wood, Warren A. (author) letter concerning the insulin adsorption controversy, 232
World Health Organization, Working Party (authors) Abuse of Medicines, I. Self Medication, 16; II. Prescription Medicines, 94; III. General Recommendations, 172
World Health Organization Report, Abuse of Medicines, I. Self Medication, 16; II. Prescription Medicines, 94; III. General Recommendations, 172
Wycillin Syringes, dangers in use of (letter) 418; reply to (letter) 605
Wykes, Arthur A. (author) letter concerning the Toxicological Information Symposium, 290

X-Y-Z

Yosselson, Shimona (author) Drugs and Nutrition, 8
Zeisler, John A., Jr. (author) letter concerning the need for OTC drug instruction to the public, 467
Zelnio, Robert N. (co-author) Results of a Preliminary Study of Consumer Attitudes on Hypertension Screening by Pharmacists, 283
Zilz, David A. (co-author) Medication Data Sheets — An Aid to Patient Education, 448
Zinc, in IV solutions, 74; leached from Stoppers (ab) 664

ADVERTISERS

American Institute of the History of Pharmacy
Bicentennial Packet, Jl-385, S-528
American Medical Association
Fat Emulsions in Parenteral Nutrition, S-548
American Society of Hospital Pharmacists
International Pharmaceutical Abstracts, Ma-251, S-490, D-697
Applied Therapeutics, Inc.
Applied Therapeutics for Clinical Pharmacists, Ma-247
Australasian Drug Information Service, O-611
Bristol Laboratories, Inc.
Emergency Medication System, Mr-180
Burroughs-Wellcome Company
Septra®, O-558-560
Drug Intelligence & Clinical Pharmacy, Inc.
Subscription Information, Ja-ifc, F-ifc, Mr-ifc, Ap-ifc, Ma-ibc, Ju-ifc, Jl-ifc, Ag-ifc, S-ibc, N-ifc
Drug Intelligence Publications, Inc.
Biotransformation Reviews, Ap-235, Ma-273, Jl-373
Books and Tapes Available, Mr, Ap, Ma, Ju, Jl, Ag, S-center inserts, N-insert 669-676
Clinical Pharmacy Handbook for Patient Counseling, Ja-60, F-67, Mr-ibc, Ap-195, Ma-ifc, Ju-303, Jl-367, Ag-431, S-504, O-561, N-619, D-730
Drug Consultation Guide, S-ifc, O-ibc, N-675, D-ifc
Drugs, Chemicals and Blood Dyscrasias, D-728-729
The Fate of Drugs in the Organism, Mr-137
Fluids and Electrolytes, Tapes, Ja-4, F-123, Mr-131, Ap-238, Ma-282, Ju-307, Jl-371, Ag-456, O-557
Fundamentals of Clinical Pharmacokinetics, F-72-73, Mr-142-143, Ma-256-257, Ju-312-313, Ag-454-455, S-492-493, O-554-555
Guide to Drug Information, Ma-272, Ju-ibc, Jl-372, Ag-475, O-551, N-665, D-730
Handbook of Basic Pharmacokinetics, F-117, Mr-191, Ju-361, Ag-481, S-497, O-569
Handbook of Clinical Drug Data, Ju-338, Ag-474, S-491, O-602, N-618, D-730
Handbooks of IV Additive Reviews, Mr-132, O-556
Index Nominum, Ja-7, F-118, Mr-187, Ag-457, O-602
Laboratory Manual of Biopharmaceutics and Pharmacokinetics, O-602
MEDISET™, Ap-196-197; Ma-253-255, obc; Ju-354-355; Jl-378-379, obc; Ag-478-479; S-538-539; O-598-599; N-676
Perspectives on Medicines in Society, D-732
Pharmacokinetic Slide Rule, O-ibc, N-674, D-ibc
Pharmacy and the Law, Ja-6, F-71, Mr-133
Principles of Clinical Pharmacy Illustrated by Clinical Case Studies, Ag-480, O-602, D-730
Social and Economic Aspects of Drug Utilization Research, S-487, O-603, N-668, D-679
Survey of General Practice of Pharmacy, Ma-299, Ju-363, Ag-483
USAN 1975, F-83
USAN 1976, O-591, N-662, D-696
Editio Cantor
Drug Research, N-658, D-713
Flint Laboratories
Travase®, Ju-310-311, Jl-374-375, Ag-434-435
Iowa Drug Information Service, Jl-420
Eli Lilly and Company
Keflex®, Ja-ibc, F-ibc, N-obc, D-obc
Keflin® IV, Ja-3, F-70, S-obc, O-610
Kefzol® IV, Mr-obc, Ap-obc, Ag-ibc, N-615
Merrell-National Laboratories
Bentyl®, Ja-5, Mr-161, Ma-291
National Pharmaceutical Foundation Symposium
Proceedings, Jl-ibc
Personnel Placement, Ja-61-63; F-127; Mr-190; Ap-234-237, 242-243; Ma-299-300; Ju-363-364; Jl-427; Ag-482-483; S-457; O-611; N-662-663; D-731
Pharmaco, Inc.
UFO, Ja-obc, F-obc
Pharma-Tek, Inc.
Antibiotic Powders, Ju-357
Roche Laboratories, Inc.
Hospital Pharmacy Advisory Board, Jl-376-377, O-552-553, N-616, 617
Hospital Pharmacy Program, Ap-198-199, Ma-252-253, Ju-308-309
Pharmacokinetics of Valium®, Jl-368-370, S-494-496
Valium® Quiz, Mr-134-136, Ma-248-250, Ju-304-306
Winners of the 1974 Hospital Pharmacy Program, F-68-69
Winners of the 1975 Hospital Pharmacy Program, Ag-432-433; S-488-489
Smith, Kline & French Laboratories
Commitment, Ap-ibc, Ju-obc, Ag-obc, O-obc
The Upjohn Company
Cleocin® Phosphate, Mr-138-141, N-620-623